Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Oncotarget - United States
doi 10.18632/oncotarget.2741
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

ISL1 Promotes Cancer Progression and Inhibits Cisplatin Sensitivity in Triple-Negative Breast Cancer Cells

International Journal of Molecular Medicine
MedicineGenetics
2018English

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells

Pharmaceutics
Pharmaceutical Science
2018English

Retraction Note To: Suppression of the xCT–CD44v Antiporter System Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

CXCR4 Inhibitors Could Benefit to HER2 but Not to Triple-Negative Breast Cancer Patients

Oncogene
Cancer ResearchGeneticsMolecular Biology
2016English

FZD7 in Triple Negative Breast Cancer Cells

2011English

Silencing the Roadblocks to Effective Triple-Negative Breast Cancer Treatments by siRNA Nanoparticles

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2017English

Blockage of Cisplatin-Induced Autophagy Sensitizes Cervical Cancer Cells to Cisplatin

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Silencing of Casein Kinase 1 Delta Reduces Migration and Metastasis of Triple Negative Breast Cancer Cells

Oncotarget
Oncology
2018English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy